Cationic Chitosan Derivatives for the Inactivation of HIV‑1 and SARS-CoV‑2 Enveloped Viruses
Zamani E. D. Cele,
William Matshe,
Lindani Mdlalose,
Katlego Setshedi,
Kanyane Malatji,
Nompumelelo Prudence Mkhwanazi,
Thandokuhle Ntombela,
Mohammed Balogun
Affiliations
Zamani E. D. Cele
Bio-Polymer Modification and Advanced Therapeutics Laboratory, Centre for Nanostructures and Advanced Materials, Council for Scientific and Industrial Research, Pretoria, Gauteng, South Africa
William Matshe
Bio-Polymer Modification and Advanced Therapeutics Laboratory, Centre for Nanostructures and Advanced Materials, Council for Scientific and Industrial Research, Pretoria, Gauteng, South Africa
Lindani Mdlalose
Bio-Polymer Modification and Advanced Therapeutics Laboratory, Centre for Nanostructures and Advanced Materials, Council for Scientific and Industrial Research, Pretoria, Gauteng, South Africa
Katlego Setshedi
Bio-Polymer Modification and Advanced Therapeutics Laboratory, Centre for Nanostructures and Advanced Materials, Council for Scientific and Industrial Research, Pretoria, Gauteng, South Africa
Kanyane Malatji
Emerging Research Area Platform, Next Generation Health Cluster, Council for Scientific and Industrial Research, Pretoria, Gauteng, South Africa
Nompumelelo Prudence Mkhwanazi
College of Health Science, School of Laboratory Medicine and Medical Science, HIV Pathogenesis Programme, University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa
Thandokuhle Ntombela
Faculty of Science, School of Chemistry, University of the Witwatersrand, Johannesburg, South Africa
Mohammed Balogun
Bio-Polymer Modification and Advanced Therapeutics Laboratory, Centre for Nanostructures and Advanced Materials, Council for Scientific and Industrial Research, Pretoria, Gauteng, South Africa
